Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (561-570 of 759) with videos related to

Pageof 76
Sort By:
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Bone Marrow Transplantation|August 9, 2018
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete responseM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 6, 2025
Comparative performance of <sup>99m</sup>Tc-pyrophosphate vs. <sup>99m</sup>Tc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imagingGregorio Tersalvi, Patricia Carey, Armin Garmany, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Pageof 76

Showing results (561-570 of 759) with videos related to

Sort By:
Pageof 76
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Bone Marrow Transplantation|August 9, 2018
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete responseM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 6, 2025
Comparative performance of <sup>99m</sup>Tc-pyrophosphate vs. <sup>99m</sup>Tc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imagingGregorio Tersalvi, Patricia Carey, Armin Garmany, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Pageof 76